Health and Medicine
AI maps routes to heart disease
Oct. 7, 2019—Machine learning on unlabeled electronic health record data has shed light on the emergence of cardiovascular disease.
Study: personalized decision support affects intensive care
Oct. 3, 2019—For patients in pediatric intensive care who are at high risk for acute kidney injury (AKI), giving clinicians automated decision support during the electronic order entry process increased the rate of blood testing for AKI by 9%.
A step toward gastric cancer
Oct. 3, 2019—New research findings provide insight into the detrimental events that develop in response to H. pylori infection.
Team discovers one more piece to the autism puzzle
Oct. 3, 2019—Vanderbilt investigators have linked genetic mutations in a single receptor to epilepsy, autism and intellectual disability.
A catalog of DNA replication proteins
Oct. 3, 2019—Vanderbilt scientists have identified 593 proteins that are enriched at sites of DNA duplication and chromatin packaging of newly synthesized DNA.
Research team sorts out drug screen false positive results
Oct. 2, 2019—Vanderbilt investigators have identified 13 previously unknown drug compounds that cause false positive screenings for amphetamines, buprenorphine (an opioid), cannabinoids and methadone.
Pua lands NIH Director’s New Innovator Award
Oct. 1, 2019—Heather Pua, MD, PhD, one of 60 investigators to receive the 2019 NIH Director’s New Innovator Award, will explore a novel type of cell signaling by RNAs in allergic airway inflammation.
Study shines light on architecture of kidney disease
Sep. 25, 2019—A study of 280,000 U.S. veterans, including 56,000 African Americans, has identified in greater detail than ever before the genetic architecture of kidney function and chronic kidney disease (CKD), according to researchers at Vanderbilt University Medical Center and their colleagues.
Diabetes drug study explores cardiovascular risks for patients with kidney disease
Sep. 25, 2019—An observational study using medical record information from nearly 50,000 U.S. military veterans sheds new light on which drugs are best for patients with Type 2 diabetes and one of its common complications, kidney disease.
Treating C. diff: new purpose for an old drug?
Sep. 24, 2019—An inexpensive generic drug once used to prevent gastrointestinal ulcers in people taking daily NSAIDs protects against C. diff infection in mice.
Tailoring treatment for heart defect
Sep. 23, 2019—By defining the clinical and genetic factors that predict treatment response, Vanderbilt investigators aim to personalize therapy for a common heart complication in preterm infants.
Guengerich, Sanders-Bush named ASPET fellows
Sep. 20, 2019—Vanderbilt University’s F. Peter (Fred) Guengerich, PhD, and Elaine Sanders-Bush, PhD, are among 22 prominent scientists named this week to the inaugural class of fellows of the American Society for Pharmacology and Experimental Therapeutics (ASPET).